Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

rthritis. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the availability of corporate partners, (x)
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  LABSCO, the leading specialty ... products to hospitals, physician office laboratories and ... distributorship agreement with Sysmex America.  This agreement ... including the Sysmex XS-1000 i ™, Sysmex ... XN-Series Automated Hematology Analyzers. The ...
(Date:9/18/2014)... -- Casen Buswell has a rare vascular condition that causes his ... one of only 14 known cases of glomuvenous malformations plaque ... the United States , and one of only ... wave-length laser, is Methodist Children,s Hospital, a campus of Methodist ... laser available in South Texas only ...
(Date:9/18/2014)... , Sept. 18, 2014   Fruit Street Health ... an initial seed round of funding. ... led by a series of individual investors, the majority ... participated in the initial round are; Houston Cardiology ... Center Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
Breaking Medicine Technology:LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3
(Date:9/18/2014)... Older people become more physically vulnerable during bereavement, new ... hormones during bereavement changes with age, British researchers say. ... more likely to have weakened immune systems and develop ... and months after loss, we can suffer from reduced ... white blood cell and as such are essential at ...
(Date:9/18/2014)... GRAND PRAIRIE, Texas (PRWEB) September 18, 2014 ... available for the air medical transport industry, ShandsCair ... by Airbus Helicopters Inc . (AHI) at the ... Tenn. , The recently delivered and placed into service ... EC130 B4 that will be displayed at AMTC highlight ...
(Date:9/18/2014)... News) -- Daily supplements of selenium or vitamin E ... age-related cataracts among men, a new study indicates. ... could help prevent cataracts. To investigate this further, William ... School in Boston, and his colleagues examined data from ... The trial was initially designed to study prevention of ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... A group of international scientists have developed a new ... here . , The Wildlife Conservation Society (WCS)-led ... Tropical Diseases , describes the use of fecal samples ... have been exposed to the virus. This represents a ... can potentially change the way Ebola virus is studied ...
Breaking Medicine News(10 mins):Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3
... Opportunity International today,announced it has received a $4.5 million ... design, create and implement new electronic,and mobile banking technologies ... to more people in Sub-Saharan Africa. , ... by eBay founder,Pierre Omidyar and his wife Pam, has ...
... The Partnership to Fight Chronic DiseaseWASHINGTON, Feb. 24 A ... care - the first in a series of Health Care ... broad health care reform - will explore opportunities to deliver ... to promote health and incentivize better choices related to prevention ...
... Results Are InMUNDELEIN, Ill., Feb. 24 Sysmex ... and laboratory information systems developer today announced that ... industry for instrument reliability for its ninth consecutive ... In this annual report, Sysmex also ranked first ...
... women who have experienced high levels of family violence ... physical and mental health than their counterparts, found a ... Journal of Women,s Health . , "In general, there ... as depression and anxiety, and more chronic pain syndromes," ...
... review by The Lancet of the medical issues ... has reaffirmed its advice about the risks of venous thromboembolism ... increased "up to four-fold" by long-haul flight. , Dr Steen ... associated with an increase in deep venous thrombosis, which in ...
... scaling 94 flights in 9 minutes, 31 secondsCHICAGO, Feb. 23 ... up the Hancock stair climb event on Sunday, February 22. ... fight against lung disease, the third leading cause of death ... expected to raise more than $1 million to benefit Respiratory ...
Cached Medicine News:Health News:Omidyar Network Grants $4.5 Million to Opportunity International to Scale Technology-based Microfinance Services in Africa 2Health News:Omidyar Network Grants $4.5 Million to Opportunity International to Scale Technology-based Microfinance Services in Africa 3Health News:Omidyar Network Grants $4.5 Million to Opportunity International to Scale Technology-based Microfinance Services in Africa 4Health News:Making Progress on Health Reform: Where Does Fighting Chronic Disease Fit In? 2Health News:Sysmex Customer Satisfaction Ranks Highest in Independent Market Research 2Health News:Triple threat to health 2Health News:ESC reaffirms advice on cardiovascular risks associated with long-haul flights 2Health News:Over 4,000 Hustle Up the Hancock to Fight Lung Disease 2
For use with E5381 700 Circling Band (240 style)....
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Medicine Products: